Klinika Ambroziak Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases
The department focuses on immune‑mediated skin conditions, testing innovative therapies to improve safety and effectiveness for patients.
- Evaluation of novel JAK inhibitors for atopic dermatitis
- Assessment of IL‑4/IL‑13 blockade in pediatric atopic dermatitis
- Long‑term safety profiling of nemolizumab therapy
- Exploring cytokine‑targeted treatments for chronic urticaria
- Investigating immune modulation in cutaneous lupus erythematosus
With 51 active trials and 15 investigators, Klinika Ambroziak in Warsaw is a key hub for advancing immune‑related dermatology research in Europe.
Skin and Connective Tissue Diseases
Research aims to develop and compare treatments for prevalent skin disorders, seeking better control of disease activity and quality of life.
- Comparative efficacy of biologics for moderate‑to‑severe plaque psoriasis
- Testing new oral agents for hidradenitis suppurativa
- Investigating repigmentation strategies in vitiligo
- Hair‑regrowth outcomes in alopecia areata
- Evaluating topical innovations for acne vulgaris
The clinic’s dermatology unit conducts extensive trials across these conditions, contributing to therapeutic advances for patients throughout Poland.
Immune System Phenomena
Studies explore underlying immune mechanisms, biomarkers, and symptom pathways to refine diagnostic tools and personalize therapy.
- Biomarker analysis of itch severity in prurigo nodularis
- Pharmacodynamic profiling of JAK‑STAT inhibition in atopic dermatitis
- Assessment of skin microbiome changes with tralokinumab treatment
- Immune‑cell infiltration studies in cutaneous lupus erythematosus
- Evaluation of cytokine signatures in chronic inducible urticaria
These investigations support the development of targeted approaches, aligning with the site’s commitment to cutting‑edge immunodermatology.
Dermatology Clinical Research
The overall program integrates multiple therapeutic areas to test novel drugs, assess long‑term safety, and improve patient‑reported outcomes.
- Phase‑III trials comparing new biologics with established standards for moderate‑to‑severe atopic dermatitis
- Placebo‑controlled studies of topical agents for acne vulgaris
- Long‑duration safety extensions for therapies targeting hidradenitis suppurativa
- Exploratory trials of oral compounds in vitiligo management
- Head‑to‑head evaluations of systemic options for chronic spontaneous urticaria
Conducted at Klinika Ambroziak, the site’s multidisciplinary team advances dermatologic care through robust clinical investigation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 5 therapeutic areas and 15 of 44 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 43 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Incyte Corp.6trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinika Ambroziak Sp. z o.o.
lock Showing 1 of 69 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis | Bristol-Myers Squibb Services Unlimited Company | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 44 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Deucravacitinib | 5 | Unknown | 2019-12-12 | 2026-05-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.